Available Programs

Are you confident tailoring therapies for patients with psoriatic arthritis? In this 60-minute panel discussion, four faculty experts will discuss evaluating patients for potential signs and symptoms to ensure timely and accurate diagnosis, review mechanisms and clinical data for new and emerging agents, and determine patient- and disease-specific therapeutic approaches for psoriatic arthritis. Join Drs. Menter, Mease, Merola, and Craig to learn about the latest in psoriatic arthritis management.   Click on any of these links to register and start…

Join Dr Ross Camidge and Dr Mark Socinski as they share insights into the selection of precision therapy for NSCLC based on tumor biomarkers and driver mutations, and strategies to proactively address treatment-related adverse events. Click here to access this 30-minute activity worth 0.50 / AMA PRA Category 1 Credit(s)TM https://www.mycme.com/courses/precision-medicine-in-non-small-cell-lung-carcinoma-new-paradigms-and-best-practices-in-targeted-therapy-7664

Are you confident implementing recent osteoporosis recommendations in your clinical practice? Despite clear guidance, screening rates remain suboptimal and many clinicians are hesitant to implement pharmacologic therapy. This 15-minute case-based CME activity, developed by osteoporosis experts Dr Rachel Pessah-Pollack and Dr Steven Petak, addresses screening, diagnosis, treatment strategies, and patient-specific treatment considerations for osteoporosis. https://realcme.com/learner/course/2812

Are you confident diagnosing and treating patients with Alzheimer’s disease? This 30-minute video activity offers pearls to optimize care for patients with this challenging neurological disease. Join Dr Zoe Arvanitakis and Dr Marwan Sabbagh as these experts discuss the importance of an early and accurate diagnosis, review current agents and treatment strategies, and highlight emerging disease-modifying agents that could change the way Alzheimer’s disease is approached in the future. Expert insights from the 2021 AD/PD Conference are also addressed in…

Spinal muscular atrophy (SMA) is an inherited condition that places a tremendous burden on patients, families, caregivers, and healthcare providers, with patients experiencing a wide range of complications and symptoms that are detrimental to day-to-day life. Although SMA management has historically consisted of supportive care, the therapeutic landscape has changed dramatically following the recent approval of transformative medications, particularly disease-modifying therapies (DMTs) that improve motor function and survival. In this educational activity, experts in SMA seek to bring clinicians up-to-date…

Are you prepared to manage influenza in the era of COVID-19? Listen to Dr Paul G. Auwaerter’s and Dr Javeed Siddiqui’s discussion on the challenges of influenza management in the midst of the COVID-19 pandemic. Explore solutions to your questions about best practices to assess influenza via telehealth, strategies for influenza prophylaxis, and selecting antivirals for children, adolescents, and adults, including patients at high risk of influenza complications. Click here to enter this activity: https://learning.freecme.com/a/37397P2C6ABt

The landscape of maintenance treatment options for ovarian cancer has been rapidly expanding and continues to evolve as new data emerge. Maintenance therapy with poly(ADP-ribose) polymerase (PARP) inhibitors and bevacizumab has demonstrated improvements in progression-free survival. A recent trial showed that maintenance therapy involving a PARP inhibitor improved overall survival in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations. In this enduring activity, an expert will examine relevant advances in genetic biomarker testing to individualize therapy, assess recent efficacy and…

In this educational activity, faculty members Nina Delaney Wagner-Johnston, MD, and Seema A. Bhat, MD, review current efficacy and safety data for targeted therapies approved for patients with treatment-naïve or relapsed/refractory (R/R) CLL, as well as emerging strategies for treatment. They evaluate clinical trial data, along with patient- and disease-related factors, that allow for the individualization of therapy selection and sequencing of therapy in first and second lines of therapy and beyond. https://reachmd.com/programs/cme/evolving-landscape-chronic-lymphocytic-leukemia-selecting-and-managing-targeted-therapy/12643/ 

Join Dr Hossein Borghaei and Dr Kurt Schalper in this personalized adaptive learning platform as they share insights into the role of PD-L1 testing to determine the best approach to ICI therapy, current efficacy and safety data for ICI therapies in NSCLC, and how to identify and mitigate immune-related adverse events (irAEs).   Click below to enter this activity: https://spirelearning.realcme.com/learner/course/2828

Are you prepared to accurately assess the severity of atopic dermatitis (AD) across a diverse spectrum of age, comorbidities, and skin of color? Are you aware of the new and emerging targeted therapy options for mild to severe AD and the evolving physiological concepts behind their rationale? The goals of this activity are to educate pediatric and adult dermatologists, allergists, and dermatologic advanced practice providers (APPs) on the diagnosis and assessment of AD and its severity in children, adolescents, and…

Did you miss the Alzheimer’s Association International Conference (AAIC) 2021 Annual Virtual Scientific Meeting? Key advances in the diagnosis and treatment of Alzheimer’s disease (AD) were presented at the AAIC 2021 meeting, including several reports on novel biomarkers for identifying early signs of AD and late-breaking clinical data on approved and emerging treatment strategies. Join Dr Zoe Arvanitakis and Dr Marwan Sabbagh as they share important take-home messages from select abstracts presented at the AAIC 2021 meeting, and access our resource library stocked…